← Back to catalogue

Rap/Tac/CsA Control

FDA UDI

Class I (US FDA UDI)

by More Diagnostics Inc

Identity

Trade Name
Rap/Tac/CsA Control FDA UDI
Generic Name
Multiple immunosuppressant therapeutic drug monitoring IVD, control FDA UDI
Device Name
MORE DIAGNOSTICS Rap/Tac/CsA CONTROL is intended to be used as a whole blood precision control product for the measurement of rapamycin, tacrolimus, and cyclosporine. FDA UDI
Model / Reference
290-1 FDA UDI
Description
MORE DIAGNOSTICS Rap/Tac/CsA CONTROL is intended to be used as a whole blood precision control product for the measurement of rapamycin, tacrolimus, and cyclosporine. FDA UDI

Identifiers

Catalog Number
290-1 FDA UDI
Primary DI / UDI-DI
00856743007215 FDA UDI
510(k) Number
K050125 FDA UDI
FDA Product Code
JJY FDA UDI
GMDN Term
Multiple immunosuppressant therapeutic drug monitoring IVD, control FDA UDI

Classification

Device Class
Class I FDA UDI
Regulation Number
862.1660 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

Yes

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

Yes

FDA UDI

Category: Multiple immunosuppressant therapeutic drug monitoring IVD, control

Rap/Tac/CsA Control by More Diagnostics Inc — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Multiple immunosuppressant therapeutic drug monitoring IVD, control.

Cleared under the same submission

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI 505a748a-4f93-4fd6-91c9-acf5e9029ed9 37 fields · synced Jun 7, 2026